The stock of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a huge mover today! About 6.09M shares traded hands or 190.00% up from the average. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has risen 34.62% since March 2, 2016 and is uptrending. It has outperformed by 26.36% the S&P500.
The move comes after 7 months positive chart setup for the $123.51M company. It was reported on Oct, 5 by Barchart.com. We have $9.32 PT which if reached, will make NASDAQ:AUPH worth $171.68M more.
Analysts await Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to report earnings on November, 11. They expect $-0.14 EPS, up 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.14 actual EPS reported by Aurinia Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.”
More news for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) were recently published by: Investorplace.com, which released: “Aurinia Pharmaceuticals Inc (AUPH) Makes Comeback on Encouraging Trial Data” on September 30, 2016. Seekingalpha.com‘s article titled: “Aurinia Pharmaceuticals Share Price Being Unfairly Punished” and published on August 31, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.